Enveric Biosciences (NASDAQ:ENVB) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Enveric Biosciences (NASDAQ:ENVB) from a hold rating to a sell rating in a research report sent to investors on Saturday morning.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Enveric Biosciences in a research note on Friday, July 17th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Enveric Biosciences presently has a consensus rating of “Sell”.

Enveric Biosciences Price Performance

ENVB opened at $1.53 on Friday. The company has a market capitalization of $5.65 million, a price-to-earnings ratio of -0.07 and a beta of 1.13. The business’s 50-day moving average price is $1.44 and its two-hundred day moving average price is $2.12. Enveric Biosciences has a 1 year low of $1.25 and a 1 year high of $17.64.

Enveric Biosciences (NASDAQ:ENVB) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.76) earnings per share for the quarter.

About Enveric Biosciences

Enveric Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel psychedelic-based therapeutics for the treatment of psychiatric and neurological disorders. The company’s research platform leverages proprietary medicinal chemistry to design, synthesize and optimize molecules derived from established psychoactive compounds, with a goal of improving safety, efficacy and tolerability compared with traditional formulations.

Enveric’s preclinical pipeline features synthetic analogs of ibogaine, psilocybin and MDMA, each engineered to enhance therapeutic outcomes in conditions such as post-traumatic stress disorder, major depressive disorder and anxiety.